Any Willing Provider and Freedom of Choice laws restrict the ability of managed care entities, including pharmacy benefit managers, to selectively contract with providers. The managed care entities argue this limits their ability to generate cost savings, while proponents of the laws suggest that such selective contracts limit competition, leading to an increase in aggregate costs. We examine the effect of state adoption of such laws on total state healthcare spending, finding that any willing provider/freedom of choice laws are associated with cost increases of at least 3 percent. These results suggest that these laws are harmful from a spending perspective
Medicare Part D began coverage of prescription drugs in 2006. Rather than setting pharmaceutical pri...
It is no secret that many Americans are less than happy with their health care coverage – either d...
Over the past several years, many states introduced legislation that protects a pharmacist’s decisio...
Any Willing Provider and Freedom of Choice laws restrict the ability of managed care entities, inclu...
Abstract: Any Willing Provider and Freedom of Choice laws restrict the ability of managed care enti...
Selective contracting in health care involves contractual arrangements among insurers and health car...
Abstract As managed care has spread, so has legislation to force plans to con-tract with any willing...
The last half-century has witnessed a dramatic rise in both health care spending and associated effo...
The question of prescription drug pricing and affordability has assumed far greater salience for Ame...
Pharmaceutical costs have been rising dramatically since 1995, growing 16.6% in 1998 alone. This rat...
This Note will discuss how the PPACA’s abbreviated approval pathway for biological products creates ...
Recently, many US employers have adopted less generous prescription drug benefits. In addition, the ...
Much scholarship has considered whether health care - and insurance - should be distributed by volun...
This study examines the effects of “any willing provider” (AWP) and “freedom of choice” (FOC) laws o...
The cost of brand-name drugs in the United States is up to four times higher than in other countries...
Medicare Part D began coverage of prescription drugs in 2006. Rather than setting pharmaceutical pri...
It is no secret that many Americans are less than happy with their health care coverage – either d...
Over the past several years, many states introduced legislation that protects a pharmacist’s decisio...
Any Willing Provider and Freedom of Choice laws restrict the ability of managed care entities, inclu...
Abstract: Any Willing Provider and Freedom of Choice laws restrict the ability of managed care enti...
Selective contracting in health care involves contractual arrangements among insurers and health car...
Abstract As managed care has spread, so has legislation to force plans to con-tract with any willing...
The last half-century has witnessed a dramatic rise in both health care spending and associated effo...
The question of prescription drug pricing and affordability has assumed far greater salience for Ame...
Pharmaceutical costs have been rising dramatically since 1995, growing 16.6% in 1998 alone. This rat...
This Note will discuss how the PPACA’s abbreviated approval pathway for biological products creates ...
Recently, many US employers have adopted less generous prescription drug benefits. In addition, the ...
Much scholarship has considered whether health care - and insurance - should be distributed by volun...
This study examines the effects of “any willing provider” (AWP) and “freedom of choice” (FOC) laws o...
The cost of brand-name drugs in the United States is up to four times higher than in other countries...
Medicare Part D began coverage of prescription drugs in 2006. Rather than setting pharmaceutical pri...
It is no secret that many Americans are less than happy with their health care coverage – either d...
Over the past several years, many states introduced legislation that protects a pharmacist’s decisio...